Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 14, 2016 5:18 AM ET


Company Overview of f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.

Company Overview

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H., a biopharmaceutical company, designs, develops, and manufactures novel bispecific monoclonal antibodies for the treatment of serious diseases with a focus on immuno-oncology and inflammatory diseases. It offers Modular Antibody Technology, a proprietary engine that generates bispecific antibodies; Fcab, which offers a fundamentally new binding region within an antibody; mAb2 bispecific monoclonal antibodies; and IP portfolio, including patents, trademarks, and trade secrets. The company was founded in 2006 and is headquartered in Vienna, Austria. It has a research site in Cambridge, the United Kingdom.

Schwarzenbergplatz 7

Vienna,  1030


Founded in 2006


43 72055 4215


43 865 55 56

Key Executives for f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.

Chief Executive Officer
Chief Financial Officer
Chief Business Officer
Vice President of Development
Age: 56
Vice President of Immunology
Compensation as of Fiscal Year 2015.

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Key Developments

F-Star Biotechnology Limited Partners with AbbVie, Inc

F-star Biotechnology Limited has entered into a collaboration and license agreement with AbbVie Inc. to research and develop bispecific antibodies in immuno-oncology. Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several bispecific monoclonal antibodies (mAb2) drug development candidates from these Fcabs. The AbbVie research activities for this collaboration will be led by AbbVie Biotherapeutics.

F-Star Announces the Appointment of Dr. Neil Brewis as Chief Scientific Officer

F-star announced the appointment of Dr. Neil Brewis as Chief Scientific Officer. Dr. Brewis joins F-star from GlaxoSmithKline (GSK) where as Vice President, Head of Biopharmaceutical Research he led a global team of 300 scientists who advanced numerous monoclonal antibodies, antibody fragments, and protein therapeutics from target validation into early clinical development. This involved leading teams focused on pipeline discovery, platform innovation, translational medicine, clinical immunology, manufacturing process research, and cell line development. Dr. Brewis has 20 years' experience in drug discovery and development and prior to joining GSK, he played a key leadership role, as Head of Research, in the success of building Domantis until the company was acquired by GSK in 2007.

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Presents at BIO-Europe 2015, Nov-02-2015

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at